234 INFLUENCE OF TUMOR SIZE ON PROGRESSION FREE AND OVERALL SURVIVAL IN A COHORT OF CONSECUTIVE RENAL CELL CANCER PATIENTS WITH LONG-TERM FOLLOW UP

2009 ◽  
Vol 8 (4) ◽  
pp. 179
Author(s):  
S. Zastrow ◽  
I. Von Bar ◽  
M.O. Grimm ◽  
M. Fröhner ◽  
S. Leike ◽  
...  
Keyword(s):  
Overall Survival ◽  
Cancer Patients ◽  
Renal Cell Cancer ◽  
Tumor Size ◽  
Renal Cell ◽  
Cell Cancer ◽  
Long Term Follow Up

Long-term follow-up in patients with metastatic renal cell cancer not treated with IL-2

2005 ◽  
Vol 23 (16_suppl) ◽  
pp. 4597-4597
Author(s):  
V. K. Chand ◽  
J. Sidloski ◽  
G. Clamon ◽  
R. J. Hohl
Keyword(s):  
Renal Cell Cancer ◽  
Renal Cell ◽  
Cell Cancer ◽  
Metastatic Renal Cell Cancer ◽  
Long Term Follow Up

Toxicities of axitinib, sunitinib and temsirolimus: implications for progression-free and overall survival in metastatic renal cell cancer

2020 ◽  
Author(s):  
Annemarie Uhlig ◽  
Johannes Uhlig ◽  
Lutz Trojan ◽  
Michael Woike ◽  
Marianne Leitsmann ◽  
...  
Keyword(s):  
Overall Survival ◽  
Cancer Patients ◽  
Skin Reaction ◽  
Renal Cell Cancer ◽  
Renal Cell ◽  
Cell Cancer ◽  
Progression Free Survival ◽  
Cox Models ◽  
Metastatic Renal Cell Cancer ◽  
Hand Foot Skin Reaction

The aim of this study was to evaluate the association between axitinib, sunitinib and temsirolimus toxicities and patient survival in metastatic renal cell cancer patients. Overall survival (OS) and progression-free survival (PFS) of metastatic renal cell cancer patients from the prospective multicenter STAR-TOR study were assessed using multivariable Cox models. A total of 1195 patients were included (n = 149 axitinib; n = 546 sunitinib; n = 500 temsirolimus). The following toxicities significantly predicted outcomes: hand–foot skin reaction (hazard ratio [HR] = 0.29) for PFS with axitinib; stomatitis (HR = 0.62) and pneumonitis (HR = 0.23) for PFS with temsirolimus; stomatitis (HR = 0.52) and thrombocytopenia (HR = 0.6) for OS with temsirolimus; fatigue (HR = 0.71) for PFS with sunitinib; hand–foot skin reaction (HR = 0.56) and fatigue (HR = 0.58) for OS with sunitinib. In conclusion, in metastatic renal cell cancer, axitinib, sunitinib and temsirolimus demonstrate specific toxicities that are protective OS/PFS predictors.

scholarly journals Recurrent renal cell cancer: 10 years or more after nephrectomy

2013 ◽  
Vol 4 (2) ◽  
pp. 45 ◽  
Author(s):  
Emmanuel Abara ◽  
Iolanda Chivulescu ◽  
Nilam Clerk ◽  
Pablo Cano ◽  
Alexis Goth
Keyword(s):  
Renal Cell ◽  
Cell Cancer ◽  
Therapeutic Agents ◽  
Health Care Practitioners ◽  
Canadian Health ◽  
Long Term Follow Up ◽  
Canadian Health Care ◽  
Localized Renal Cell Carcinoma

Localized renal cell carcinoma (RCC) responds well to surgery.Patients often question how long they have to be on surveillanceafter their surgery. Several follow-up patterns have been describedin the literature. Until 2009, no published established Canadianguidelines existed to assist Canadian health-care practitioners inthe surveillance of these patients. We present 3 cases of RCC thatrecurred 10 years or longer after the initial nephrectomy. Thesecases emphasize the need for careful long-term follow-up, as recommendedin the Canadian Urological Association guidelines.We also discuss the optimism of prolonged disease survival inthe era of novel therapeutic agents that target angiogenesis.

Impact of tumor size on the long-term survival of patients with early stage renal cell cancer

2005 ◽  
Vol 23 (1) ◽  
pp. 50-54 ◽  
Author(s):  
M. Kuczyk ◽  
G. Wegener ◽  
A. S. Merseburger ◽  
A. Anastasiadis ◽  
S. Machtens ◽  
...  
Keyword(s):  
Renal Cell Cancer ◽  
Tumor Size ◽  
Renal Cell ◽  
Early Stage ◽  
Cell Cancer ◽  
Term Survival ◽  
Long Term Survival

Prognostic factors and long-term survival in renal cell cancer patients

2009 ◽  
pp. 1-7
Author(s):  
Kaisa Sunela ◽  
Matti Kataja ◽  
Eero Lehtinen ◽  
Tapio Salminen ◽  
Paula Kujala ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
Cancer Patients ◽  
Renal Cell Cancer ◽  
Renal Cell ◽  
Cell Cancer ◽  
Term Survival ◽  
Long Term Survival
Sign in / Sign up

Export Citation Format

Share Document